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Abstract
The inverse relationship between zinc (Zn//) and prolactin (PRL) was detected in in vitro studies,
whereas in vivo results are contradictory. In order to evaluate this controversial subject we
studied patients with hyperprolactinemia. Basal serum Zn
+/ levels and serum PRL response to
acute and chronic oral Zn administration were evaluated in seven patients with prolactinomas
and one with idiopathic hyperprolactinemia. Serum PRL levels did not change after acute oral
Zn administration (37.5 mg), although Zn
+/ levels increased from 1.11 +/- 0.15 to 2.44 _+ 0.39
pg/mL (p < 0.05). Zn administration (47.7 mg daily) during 60 days increased serum Zn levels
from 1.11 + 0.15 to 1.59 _+ 0.58 IJg/mL (p < 0.05) but caused no change in serum PRL levels. The
TRH tolerance test (200 Ig) was performed before and after 60 days of Zn
/+ administration, and
PRL response to TRH was unchangeable and similar in both tests. We concluded that acute or
chronic Zn
// administration does not inhibit PRL secretion in basal condition or by TRH effect in
hyperprolactinemic patients.
Introduction
Zn plays an important role in animal and human metabolism, as a constituent or activating co-
factor of more than 300 different enzymes. The spectrum of their action includes intermediary
metabolism, DNA and RNA synthesis, gene expression, immunocompetence, behaviour, and
several endocrine functions []. Many studies have shown that Zn
+/ can interact with many
hormones especially with PRL [z3]. Several in vitro studies showed that Zn was capable of
inhibiting basal and TRH-stimulated PRL release, in a dose dependent manner, in bovine and rat
pituitary cells [4,.6]. An inverse relationship between serum Zn+/and plasma PRL levels is a
common finding in human chronic renal failure. The administration of oral Zn to a group of
uremic hypozincemic men decreased their high PRL levels and these levels were inversely
correlated to serum Zn concentrations[7].
In normal male and female subjects and in lambs, acute Zn administration decreased plasma
PRL levels [.], although in another report a similar effect was not observed in normal and
hyperprolactinemic women [9]. Furthermore, Travaglini et al. described low plasma Zn
+/ levels in
eight patients with prolactinoma, which increased to normal levels after bromocriptine-induced
PRL normalization [lo].
These data point to an inverse relationship between Zn
// and PRL, suggesting that this trace
element plays an important role in PRL physiology. It was even hypothesized by Koppelman that
PRL is a major Zn regulating hormone and that the suppression of PRL by Zn is a part of a
negative feedback regulatory system
The aim of this paper is to study basal serum Zn levels, the serum PRL levels after acute and
chronic Zn
*/ administration, and TRH-induced PRL secretion after chronic Zn administration in
hyperprolactinemic patients.
Material and Methods
Subjects
Hyperprolactinemic patients were studied after obtaining written informed consent and approval
of the University Ethical Board. The patients examined (seven females and one male) had a
mean age of 34 +/- 12.3 years (20-52 years) and all but one had radiological evidence of
macroadenomas, this one having a normal magnetic resonance image. Patients with
ophthalmological and neurological complications and hypopituitarism were excluded.
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Protocol
The tests were started at 8:00 a.m. at least 12 h after the last meal. A device for infusion was
initially inserted into an antecubital vein. All subjects maintained resting decubitus throughout the
tests. Blood for Zn determinations were obtained without tourniquet and all syringes, tubes and
pipettes were Zn
/+ free. All samples were stored at-20 -C.
TRH Stimulation Test
Saline infusion was initiated at approximately 8:00 am. Two blood samples for PRL determination
were collected 30 min and immediately before an i.v. bolus dose of 200 #g of TRH and after
every 15 min during 90 min.
Acute Oral Zn
+/ Administration
Blood samples for serum Zn
/+ and PRL determinations were collected 30 min and immediately
before 37.5 mg of oral Zn as ZnSO4.7H20 diluted in 20 mL of deionized water and every 30 min
during 240 min.
Chronic Oral Zn Administration
All patients received 15.9 mg of elemental zinc, three times a day during 60 days. Basal samples
for Zn
+/ and PRL determinations were collected on the 7th, 30th and 60th day. On the 60th day a
new TRH stimulation test was performed as described above.
Biological Analysis
Serum Zn/+was determined in duplicate with an atomic absorption spectrophotometer
(Atomspeck model H-1170, Hilger & Watts, UK) as reported [2]. The intra-assay error was 2.5%
and sensitivity was 0.02 #g/mL. Hemolyzed samples were discarded. Serum PRL concentrations
were measured in duplicate by radioimmunoassay (Diagnostic Products Corporation, USA). The
sensitivity of the assay was 1.3 ng/ml and the intra- and interassay coefficients of variations were
6% and 11% respectively.
Statistical analysis
All data are given as the mean + SD. The difference between means was evaluated by the
unpaired Student’s t-test. Tukey’s multiple comparison test compared all pairs of columns.
Correlation was analyzed according to Spearman’s method. Significance was taken as p < 0.05
using a significant level of 5%.
Results
Basal serum Zn
// and serum PRL levels
Mean basal serum Zn
/+ levels of hyperprolactinemic patients were significantly lower than in
normal individuals, 1.11 +/- 0.15 and 1.33 +/- 0.17 pg/mL, respectively, p < 0.05 (Table I). On the
other hand, PRL values were higher than in controls, 533 + 585 and 13.9 + 3.3 ng/mL,
respectively (Table I).
Acute oral Zn
// ingestion
There was a significant increase of serum Zn
+/ levels during the test when compared with the
basal levels, p < 0.05 (Table I). Serum PRL did not change as compared to basal levels, not
significantly different, p (Table I), and no correlation was observed between Zn
/+ and PRL (r
0.27, p > 0.05).
Table I: Acute oral Zn
// administration to hyperprolactinemic patients (n=8)
Time (min) Zn++ (i.Jg/mL) p value ’ PRL (nc;j/mL1 io value b
0 1.11 + 0.15 533 + 585
30 1.47 + 0.44 > 0.05 517 + 606 > 0.05
60 1.85 + 0.53 > 0.05 533 + 604 > 0.05
90 2.11 +/- 0.53 < 0.05 534 + 629 > 0.05
120 2.44 + 0.39 < 0.05 503 + 536 > 0.05
150 2.36 + 0.58 < 0.05 504 + 522 > 0.05
180 2.24 + 0.71 < 0.05 445 +476 > 0.05
210 2.10 + 0.67 < 0.05 422 + 456 > 0.05
240 1.74 + 0.59 > 0.05 430 + 460 > 0.05
Reference range limits 1.33 + 0.17 13.99 + 3.30
’a valuesa’re expressed as mean :!: SD. u P values were obtained from one-way analysis of variance (ANOVA), using
Tukey’s multiple comparison test, and p < 0.05 was accepted as significant,
c A reference range study was performed in
which serum (Zn//) and plasma (PRL) samples from 17 fasting volunteers, including 9 males and 8 females, age-
matched, were assayed in our laboratory.
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Chronic oral Zn ingestion
Chronic Zn
// administration, during 60 days, was followed by an increase of serum Zn
/+ levels as
compared to basal values, but they were not significantly difference, p > 0.05, and serum PRL
levels did not change compared to initial basal values, p > 0.05 (Table II). TRH-stimulated PRL on
the 60th day of chronic Zn
+/ administration was similar to the test performed before Zn
/+
administration (Table III). Again, no significant correlation was detected between Zn
/+ and PRL (r
-0.25, p > 0.05).
Table I1" Chronic oral Zn
+/ administration to hperprolactinemic patients (n=8). Da’s Zn (IJcj/mL) p value PRL (ncj/mL) p value
0 1.11 + 0.15" 533 +/- 585"
7 1.32 +/- 0.15 > 0.05 486 +/- 438 > 0.05
30 1.43 +/- 0.30 > 0.05 661 +/- 598 > 0.05
60 1.59 + 0.58 > 0.05 563:1:605 > 0.05
values are expressed as mean + SD.
b p values were obtained from one-way analysis of variance (ANOVA), using
Tukey’s multiple comparison test, and p < 0.05 was accepted as significant.
Table II1: PRL values during TRH stimulation test (200 pg) before and after chronic oral Zn
/+
,administration (15.9m tid for 60 da)/s) in hyperprolactinemic patients In=8/.
PRL (ng/mL) p value Zn (pg/mL)
Basal Peak Basal
Before Zn 423 +/- 439 587 + 572 > 0.05 1.11 +/- 0.15"
After Zn
+/ 560 + 608 672 + 650 > 0.05 1.59 +/- 0.58
p value > 0.05 > 0.05 > 0.05 > 0.05
a values are expressed as mean + SD.
b P values were obtained from unpaired test, using two-tail p value to compare
two groups, and p < 0.05 was accepted as significant.
Discussion
A wide number of in vitro studies show an inverse relationship between Zn
// and PRL. Zn
+/
interferes physiologically and pharmacologically in the synthesis, storage, release and peripheral
action of PRL. Interaction with calcium-channels, calcium-calmodulin complex, adenylate cyclase,
secretory granules, membrane stabilization and membrane receptors are some of proposed
mechanisms of Zn
// involvement in PRL secretion, as was reviewed by Brand&o-Neto et al. []. In
a previous study we have shown that oral Zn+/administration to normal male and female
individuals induced a significant decrease in PRL levels, suggesting that acute hyperzincemia can
inhibit basal PRL secretion [2]. These data support the hypothesis of Koppelman [11] that PRL
regulates the uptake and distribution of Zn
+/ and that PRL suppression by this element could
represent a negative feedback loop in a similar manner to calcium and PTH.
In this study, our patients with hyperprolactinemia showed lower basal serum Zn
// levels (Table
I), results similar to that shown by Tavaglini et al. [lo]. They are in accordance with the hypothesis
of Koppelman [], although, later, Koppelman et al. [] were unable to observe the same inverse
relationship. The relatively low serum PRL levels of Koppelman’s patients as compared with
Travaglini’s and ours may explain these conflicting results.
In search of this hypothetical loop, we have acutely administered Zn
+/ to hypozincemic
hyperprolactinemic patients, which did not result in a decrease of serum PRL levels. Koppelman
et al. [9] did not find a serum PRL decrease after Zn/+administration to normozincemic
hyperprolactinemic patients. Normalization of serum Zn
+/ levels induced by chronic zinc
administration to our hyperprolactinemic patients was also not followed by a decrease in serum
PRL levels, corroborating data of Travaglini et al. [lo]. Before Zn
+/ administration, all patients were
submitted to dynamic tests (insulin and GnRH tolerance tests) and no abnormal secretion of GH,
LH, FSH, TSH or cortisol was detected.
In humans, acute Zn
+/ administration to normal individuals and hyperprolactinemic patients with
normal serum Zn
/+ levels was not followed by a decrease in TRH-stimulated PRL release [9]. In
our patients with decreased basal Zn
+/ levels, chronic administration of this trace element did not
change the TRH-induced PRL release, despite of a normalization of serum Zn
+/ levels. Initially,
we speculated if prolactinoma was out of physiological control but investigations on 15 healthy
161Vol. 6, No. 3, 1999 Effect of,4cute and Chronic Oral Zinc Administration
in Hyperprolactinemic Patients
men submitted to simultaneous Zn and TRH tolerance tests demonstrated no interference of
Zn
/+ on TRH-stimulated PRL secretion [12]. These results practically contradict the hypothesis that
the lack of lactotrophs response by Zn stimulus was a characteristic of autonomy by the
prolactinoma, probably due to structural and functional changes in lactotrophs. On the other
hand, these data are in conflict with all in vitro studies that have shown inhibition of basal and
TRH-stimulated PRL release from intact anterior pituitary glands during static incubation and
perifused dispersed pituitary cells [3-6]. However, the in vitro experiments do not reproduce the
intercellular communication by chemical mediators like endocrine, paracrine, synaptic and gap
junctions observed in vivo
In summary, the present study has shown hypozincemia and no inhibition of TRH-induced PRL
secretion during acute and chronic Zn
+/ administration in hyperprolactinemic patients. The fact
that zinc administration does not inhibit PRL levels argues against the proposal of using zinc as a
therapeutical agent in the treatment of hyperprolactinemic patients.
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